Also, Resverlogix, independent of the DSMB analyses/recommendations and also blinded to the trial data, has the option to make trial modifications including  but not limited to, number of patients and target MACE events. For example, to allow for a certain number of USA patients, Resverlogix could increase enrollment beyond the 2400. This could be based on regional and FDA concerns, not on statistics and trial data. As of right now, it seems like no plan for USA patients. But SSRA results may change that.